中国药业
中國藥業
중국약업
China Pharmaceuticals
2015年
17期
69-70
,共2页
消癌平注射液%药品不良反应%中药注射剂%合理用药
消癌平註射液%藥品不良反應%中藥註射劑%閤理用藥
소암평주사액%약품불량반응%중약주사제%합리용약
XiaoaiPing Injection%ADR%Traditional Chinese Medicine Injection%clinical analysis%retrosPective study
目的：了解消癌平治疗肝癌致不良反应的特点及影响因素，为临床合理用药提供参考。方法对某院2009至2013年收集到的13例消癌平注射液治疗肝癌致药品不良反应（ADR）报告进行分析，包括患者的基本概况、用药剂量及溶剂、联合用药情况、ADR发生及持续时间、ADR累及系统/器官和主要临床表现、治疗及转归等。结果13例ADR中，男性患者较多（61.54％），平均年龄为（56.31±13.87）岁；ADR大部分发生在首次给药后，最快为用药2 min后，最慢为用药2 d后；以全身性损害最常见（33.33％）；ADR经处理后均治愈或停药后自愈。结论消癌平注射液应严格按药品说明书使用，并尽量避免联合用药，使用时需严密监测患者体征及症状。临床中应重视消癌平注射液致ADR的监测及报告工作。
目的：瞭解消癌平治療肝癌緻不良反應的特點及影響因素，為臨床閤理用藥提供參攷。方法對某院2009至2013年收集到的13例消癌平註射液治療肝癌緻藥品不良反應（ADR）報告進行分析，包括患者的基本概況、用藥劑量及溶劑、聯閤用藥情況、ADR髮生及持續時間、ADR纍及繫統/器官和主要臨床錶現、治療及轉歸等。結果13例ADR中，男性患者較多（61.54％），平均年齡為（56.31±13.87）歲；ADR大部分髮生在首次給藥後，最快為用藥2 min後，最慢為用藥2 d後；以全身性損害最常見（33.33％）；ADR經處理後均治愈或停藥後自愈。結論消癌平註射液應嚴格按藥品說明書使用，併儘量避免聯閤用藥，使用時需嚴密鑑測患者體徵及癥狀。臨床中應重視消癌平註射液緻ADR的鑑測及報告工作。
목적：료해소암평치료간암치불량반응적특점급영향인소，위림상합리용약제공삼고。방법대모원2009지2013년수집도적13례소암평주사액치료간암치약품불량반응（ADR）보고진행분석，포괄환자적기본개황、용약제량급용제、연합용약정황、ADR발생급지속시간、ADR루급계통/기관화주요림상표현、치료급전귀등。결과13례ADR중，남성환자교다（61.54％），평균년령위（56.31±13.87）세；ADR대부분발생재수차급약후，최쾌위용약2 min후，최만위용약2 d후；이전신성손해최상견（33.33％）；ADR경처리후균치유혹정약후자유。결론소암평주사액응엄격안약품설명서사용，병진량피면연합용약，사용시수엄밀감측환자체정급증상。림상중응중시소암평주사액치ADR적감측급보고공작。
Objective To investigate the characteristics and relative factors of adverse drug reactions of XiaoaiPing Injection treated in liver cancer and Provide reference for rational drug use in the clinic. Methods This study analyzed 13 cases of ADR caused by Xi-aoaiPing Injection in liver cancer treatment between 2009-2013, including the Patients' basic information,dosage,solvent,drug combi-nation,occurrence and duration time of ADR,systems-organs involved,the main clinical manifestations,treatment and outcome of ADR,etc. Results In the 13 cases of ADR,male Patients with an average age of ( 56. 31 ± 13. 87 ) accounted for higher ProPortion ( 61. 54% );ADR mostly occurred after the first administration,and the fastest was of 2 min while the slowest was after 2 d; the most common manifestation was systemic damage ( 33. 33% );ADR were cured after additional treatment or discontinuing. Conclusion The administra-tion of XiaoaiPing Injection should strictly follow the instructions and avoid drugs combination. Patients should be closely monitored of the signs and symPtoms during the clinical treatment. ADR monitoring and rePorting should be Particularly emPhasized in Patients treat-ed with XiaoaiPing Injection.
